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Background and aim: Patients suffering from chronic constipation require long-term, regular 
therapy with laxatives. Literature regarding patient preference and acceptance in polyethylene 
glycol preparations is scarce. Therefore, this research aimed to identify preference between the 
three polyethylene glycol 3350, namely Molaxole®, Movicol®, and Laxtra Orange®. Furthermore, 
taste is one of the most important factors leading to patients’ adherence, particularly when the 
treatment lasts for a long time.
Methods: In this randomized, cross-over double-blind study, 100 volunteers were recruited by 
advertisement. The volunteers were invited to taste the preparations and grade the taste using a 
five-point hedonic scale (extremely poor taste [1] to extremely good taste [5]). The volunteers 
were then asked to choose the most palatable preparation.
Results: One hundred volunteers with a mean age of 35 years (range 20–61) were randomized 
(76 females). Molaxole®, Movicol®, and Laxtra Orange® had a mean hedonic score of 2.76 (SD: 
0.82), 2.81 (SD: 0.76) and 3.12 (SD: 0.82) respectively. The hedonic taste score for Laxtra 
Orange® was significantly better than Molaxole® (P = 0.001) and Movicol® (P = 0.001). No 
difference was found between Molaxole® and Movicol® (P = 0.61). Molaxole® was the most 
preferred preparation for 19 volunteers (19%), Movicol® for 24 volunteers (25%) and Laxtra 
Orange® for 55 volunteers (56%). Two volunteers had no preference. The order in which vol-
unteers tested the preparations had no influence on the taste results. No significant differences 
in age or gender were observed.
Conclusion: Laxtra Orange® was most palatable preparation. This may have implications for 
adherence in patients with chronic constipation.
Keywords: constipation, polyethylene glycol, laxative, macrogol, molaxole, movicol, laxtra, 
medication adherence
Introduction
Chronic idiopathic constipation is a frequently reported medical disorder and reduces 
patients’ quality of life.1 The estimated prevalence in Europe is 17% and increases 
with age, especially in those over the age of 65 years.2,3
The initial management of chronic idiopathic constipation includes behavior modi-
fication and dietary changes.4 For patients who do not respond to this management, 
laxatives present an alternative therapy.1 Up to 40% of these patients use laxatives.5
A variety of laxatives are available for treating constipation: bulk forming, osmotic, 
and stimulant laxatives. Osmotic laxatives, particularly polyethylene glycol (PEG) 
preparations are trendsetting in the constipation market. PEG preparations are relatively Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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safe, inexpensive, widely used, and are even better than 
lactulose in improving stool frequency and consistency.6–8
Although these modalities may benefit some patients with 
temporary constipation, most of the patients often need to 
use these compounds on a regular basis. According to the 
literature, only 50% of patients who suffer from chronic 
diseases adhere to treatment recommendations, which results 
in suboptimal outcomes.9,10 There are numerous factors that 
affect adherence, including characteristics of the illness, 
interaction between physician and patient, the complexity 
and duration of treatment, side effects of treatment, and cost   
of   treatment.11 Furthermore, medication palatability is 
also crucial for adherence. Several studies have addressed 
the palatability of medication for different disorders, 
including hypertension, HIV , and Alzheimer’s disease.12–14 
  Pharmaceutical companies have tried to improve palatability 
by adding flavors, such as vanilla, strawberry, and citrus, 
although this is primarily in medication for children.15–17
Literature regarding patient preference and acceptance 
in PEG preparations is scarce.18–20 Therefore, we aimed to 
compare three commonly used PEG 3350 preparations, 
Molaxole®, Movicol®, and Laxtra Orange® in taste and to 
evaluate preference.
Patients and methods
A total of 100 volunteers recruited by advertising through 
posters were included in a cross-over, double-blind, random-
ized study.
Volunteers were presented with three preparations of 
25 mL in a randomized order. After tasting each sample 
without swallowing, volunteers rinsed their mouths with 
water. The samples were graded using a five-point hedonic 
scale (extremely poor taste [1] to extremely good taste [5]). 
Following this, volunteers were asked to choose the most 
palatable preparation.
This was an investigator initiated study that was approved 
by the Ethics Committee of VU Medical Center, Amsterdam, 
the Netherlands, and was in accordance with the Helsinki 
Declaration. All patients gave informed consent prior to 
participation.
Polyethylene glycol preparations
Three PEG 3350 preparations, Molaxole®, Movicol®, and 
Laxtra Orange® were chosen as these are the most commonly 
prescribed product variants. All three PEG 3350 prepara-
tions contain similar doses of macrogol, electrolytes and 
sweetener, namely 3.125 g macrogol 3350, 350.7 mg sodium 
chloride, 178.5 mg sodium hydroxide carbonate, 46.6 mg 
potassium chloride and acesulfame K (E950). Molaxole® 
additionally contains lemon flavor, Movicol® a lime/lemon 
flavor and Laxtra Orange® an orange flavor.
statistical analyses
Data analysis was performed using the statistical software 
SPSS (v 15.0; SPSS, Inc, Chicago, IL). Results were 
described as means and proportions. The Wilcoxon signed-
rank test was used to determine the difference in taste 
between the preparations. A P-value of less than 0.05 was 
considered statistically significant. When using a Bonferroni 
correction for three interdependent classes, a P-value less 
than α/3 = 0.01667 was considered statistically significant.
Results
One-hundred volunteers were randomized (mean age: 35 years 
[range: 20–61], 76 female). The mean hedonic score was 2.76 
(SD: 0.82), 2.81 (SD: 0.76) and 3.12 (SD: 0.82) for Molaxole®, 
Movicol®, and Laxtra Orange® respectively (Figure 1). The 
hedonic taste score for Laxtra Orange® was significantly higher 
than Molaxole® (P = 0.001) and Movicol® (P = 0.001). No sig-
nificant difference was found between Molaxole® and   Movicol® 
(P = 0.61). One volunteer graded all three preparations 1, 
whereas one volunteer graded all preparations 5 (Figure 1).
The order in which volunteers tested the preparations 
had no influence on the taste results. Thirty-eight (39%), 
24 (24%), and 36 volunteers (37%) found the first, second, 
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Figure  1  hedonic  taste  score  for  all  polyethylene  glycol  preparations  (Peg) 
(1 = extremely poor taste, 5 = extremely good taste); the mean hedonic score 
was 2.76 (sD: 0.82), 2.81 (sD: 0.76) and 3.12 (sD: 0.82) for Molaxole®, Movicol®, and 
Laxtra Orange®, respectively.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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and third tested preparation respectively most palatable. 
After decoding, Molaxole® was the most liked preparation 
in 19 volunteers (19%), Movicol® in 24 volunteers (25%), 
and Laxtra Orange® in 55 volunteers (56%) (Figure 2). 
Two volunteers had no preference.
There were no significant differences in age or gender 
observed.
Discussion
Nonadherence to treatment is a problem of increasing 
concern. Many patients experience difficulty with taking 
medication because of aversion to the taste, which results in 
suboptimal adherence. Although there are no easy solutions 
to this dilemma, pharmaceutical companies have tried to 
improve palatability by adding flavors to medications, such 
as vanilla, strawberry, and citrus.15–17
This randomized, double-blind study, which involved 100 
volunteers, showed that the orange flavor of Laxtra Orange® was 
significantly better tasting than the lemon flavor of   Molaxole®, 
and the lime and lemon flavor of Movicol®. No difference 
was found between Molaxole® and Movicol®. No differences 
between gender, age, or sequence of tasting were found.
PEG preparation with electrolytes is mixed with water. 
A good suggestion is to mix the PEG preparation with cold 
water, which makes it more palatable. Since all these PEG 
preparations contain electrolytes, it cannot be mixed with 
juice, coffee, or tea. However, recent studies showed that a 
PEG preparation without electrolytes is as effective and safe 
as a PEG preparation with electrolytes in the treatment of 
constipation in elderly patients and children.21,22
Limitations
There are some limitations in our study that need to be 
considered. The volunteers were only offered a small sip 
of each preparation, whereas in the real-world situation, 
a patient with constipation may need to ingest more than 
125 mL of the medication. Therefore, we cannot be sure that 
the preference is still valid for larger quantities. However, 
since a more palatable medication can improve adherence,10 
it might be worthwhile to consider Laxtra Orange® if patient 
has complaints regarding the taste.
In addition, we acknowledge that the volunteers were 
relatively young, and therefore our results may not be repre-
sentative for the whole constipated population.   Constipation 
disproportionately affects older adults and it is well recog-
nized that older adults have less sensitivity in their taste 
acuity.23 However, no apparent effect of age was found.
Conclusion
In conclusion, we found that Laxtra Orange® was the most 
favored preparation in a single test. Given the fact that the 
three tested preparations have a similar PEG and electrolyte 
content and therefore the same efficacy, for complaints about 
the taste, switching to Laxtra Orange® could improve the 
adherence of the patient.
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Figure 2 Most preferred preparation in 100 volunteers.Patient Preference and Adherence
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